is glp-1 bad for you The promise and peril of agonists: What we do (and don't) know as of August 2024 GLP-1 Medications Infographic | Medidex

Diabetes 69 , 749759 (2020)

Whilst minor amounts of energy can be produced in the cytoplasm during glycolysis, the major source of cellular energy comes from oxidative phosphorylation, which occurs in the mitochondria

A decline in estrogen levels during menopause (usually occurring in the late 40s or 50s) can contribute to the acceleration of muscle loss in women

The preservative systems in compounded formulations are typically less robust than those in manufactured products, meaning room temperature exposure degrades the medication faster

The International Diabetes Federation projected that the number of new diabetes cases is expected to reach 643 million by 2030 and 783 million by 2045